glp-1 news today oct 2 2025 Alarming rise in weight loss drug overdoses GLP-1 RA prescription trends: January

No new safety signals were observed ( The second SGLT2 inhibitor, empagliflozin, was tested in a randomized trial assessing its pharmacokinetic and pharmacodynamic profile and identifying the appropriate doses in young people with T2D aged 10 to 17 years

Millions of peoplemany without diabetes or severe obesityare now on GLP-1s

In August 2024, we surveyed 23andMe research participants about their GLP1 medication usage, focusing on those taking weight loss medication

Efficacy of Escitalopram in the Treatment of Major Depressive Disorder Compared With Conventional Selective Serotonin Reuptake Inhibitors and Venlafaxine XR: A Meta-Analysis (March 2006) Serotonergic Mechanisms Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance (2017) Doi: 10.1007/164_2016_103 Stress and Eating Behaviors (September 2013) 4 Ways to Get Good Fats Infographic (2023) Effects of Sodium Reduction on Energy, Metabolism, Weight, Thirst, and Urine Volume: Results From the DASH (Dietary Approaches to Stop Hypertension)-Sodium Trial (March 2020) Effects of Escitalopram on Sleep Problems in Patients With Major Depression or Generalized Anxiety Disorder (November 2011) Doi: 10.1007/s12325-011-0071-8.